By Drug Target Review2024-03-04T16:00:35
Treatment with Palbociclib and a compound targeting CAD increased survival to 100 percent for selected lymphoma cell lines.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-26T13:58:00Z
2026-03-18T14:47:08Z
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-07-04T10:05:58
Sponsored by Revvity
2024-02-02T15:48:26
Sponsored by Bio-Techne
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2023-02-23T14:02:18
Sponsored by bit.bio
Site powered by Webvision Cloud